What changed
The US Food and Drug Administration placed Chengdu Shengnuo Biopharm and Nanjing Chengong Pharmaceutical on Import Alert 66-40 over reported manufacturing and ingredient-verification concerns.
At Chengdu Shengnuo, inspectors reported black mould, contaminated floors, insect activity, concealed documentation and product samples poured down sinks. At Nanjing Chengong, they reported that workers approved externally sourced active ingredients without properly reviewing supplier safety and quality records. The listings were published on September 19 and October 1, 2026.
Why it matters
An import alert gives US authorities a practical border-control tool: covered shipments can be detained without examining every shipment individually. For US compounders using semaglutide or tirzepatide ingredients, that can put more weight on supplier records, testing and traceability before those ingredients enter production.
The two cases point to different weak spots. Chengdu Shengnuo’s reported problems concern basic contamination control and the credibility of its quality systems. Nanjing Chengong’s concern is less visible but just as important: a supplier’s paperwork and testing are only useful if someone properly checks them.
Chengdu Shengnuo Biotec said the FDA’s August 2026 inspection produced eight Form FDA 483 observations and that it submitted an initial response. The next meaningful question is whether the companies can satisfy the requirements for releasing covered imports.
The alert concerns ingredients used in compounded versions of medicines containing semaglutide and tirzepatide. Those compounded products are distinct from FDA-approved Ozempic, Wegovy, Mounjaro and Zepbound. The findings do not establish that every batch from either facility was contaminated or that every compounded medicine using their ingredients was unsafe.
Comments
No comments yet.